Alector ( (ALEC) ) has provided an update.
Alector, a clinical-stage biotechnology company, has secured a $50 million credit facility from Hercules Capital. This funding boosts its financial flexibility, allowing Alector to advance its pipeline, including the AL002 INVOKE-2 Phase 2 and latozinemab INFRONT-3 Phase 3 trials, and its innovative blood-brain barrier platform. With over $457 million in cash, the company is well-positioned to continue operations through 2026, enhancing its capacity to bring new treatments for neurodegenerative diseases to market.
Learn more about ALEC stock on TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
